IONS Q2 2025 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$13B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$452M+100.7% YoY

Gross Profit

$448M99.1% margin

Operating Income

$140M30.9% margin

Net Income

$124M27.3% margin

EPS (Diluted)

$0.68

QoQ Revenue Growth

+243.5%

Cash Flow

Operating Cash Flow

$151M

Free Cash Flow

$137M

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$3.0B

Total Liabilities

$2.4B

Stockholders' Equity

$632M

Cash & Equivalents

$297M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$452M	$225M	+100.7%
Gross Profit	$448M	$221M	+102.6%
Operating Income	$140M	-$66M	+311.6%
Net Income	$124M	-$66M	+286.4%

Revenue Segments

Commercial Member

$103M54%

Royalty

$70M36%

Product

$19M10%